Media coverage
1Media coverage
Title A Phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2 Media name/outlet National AIDS Treatment Advocacy Project Country United States Date 4/30/15 Persons Eric J Lawitz